Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.33 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863693 | 0.82 | — | — | |
| SCHEMBL29154673 | 0.82 | — | — | |
| SCHEMBL487316 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10CHRM5CHRM1 | |
| SCHEMBL10813466 | 0.76 | ALOX15 (0.39) | LMNACHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2586277 | 0.76 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10CHRM5CHRM1 | |
| SCHEMBL30863691 | 0.76 | TP53 (0.35) | — | |
| SCHEMBL6383645 | 0.75 | — | — | |
| SCHEMBL577216 | 0.75 | — | — | |
| SCHEMBL3787585 | 0.74 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10CHRM5CHRM1 | |
| Benzene SCHEMBL28697969 | 0.74 | ALDH1A1 (0.38) | ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091980-A1 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | NVISION IMAGING TECHNOLOGIES GMBH (DE) | 2025-03-20 | — | — | US | disclosed |
| US-12110270-B2 | Systems and methods for generation of hyperpolarized materials | NVISION IMAGING TECHNOLOGIES GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| EP-4313174-A1 | SYSTEMS AND METHOD FOR GENERATION OF HYPERPOLARIZED MATERIALS | NVision Imaging Technologies GmbH (DE) | 2024-02-07 | — | — | EP | disclosed |
| US-20240018087-A1 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | NVISION IMAGING TECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| WO-2022200859-A1 | SYSTEMS AND METHOD FOR GENERATION OF HYPERPOLARIZED MATERIALS | NVision Imaging Technolgies GmbH (DE) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110270-B2 | Systems and methods for generation of hyperpolarized materials | GLS2, HNMT, FH | ALDH1A1 2576/4885LMNA 806/4885HSD17B10 1928/4885 |
| US-20240018087-A1 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | GLS2, HNMT, FH | ALDH1A1 2576/4885LMNA 806/4885HSD17B10 1928/4885 |
| US-20250091980-A1 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | GLS2, HNMT, FH | ALDH1A1 2576/4885LMNA 806/4885HSD17B10 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.